Literature DB >> 34081687

Excess Death Estimates in Patients with End-Stage Renal Disease - United States, February-August 2020.

Robert Ziemba, Kyle N Campbell, Tsu-Hsuan Yang, Sara Eve Schaeffer, Kelly M Mayo, Paul McGann, Shalon Quinn, Jesse Roach, Edwin D Huff.   

Abstract

End-stage renal disease (ESRD) is a condition in which kidney function has permanently declined such that renal replacement therapy* is required to sustain life (1). The mortality rate for patients with ESRD in the United States has been declining since 2001 (2). However, during the COVID-19 pandemic, ESRD patients are at high risk for COVID-19-associated morbidity and mortality, which is due, in part, to weakened immune systems and presence of multiple comorbidities (3-5). The ESRD National Coordinating Center (ESRD NCC) supports the Centers for Medicare & Medicaid Services (CMS) and the ESRD Networks†,§ through analysis of data, dissemination of best practices, and creation of educational materials. ESRD NCC analyzed deaths reported to the Consolidated Renal Operations in a Web-Enabled Network (CROWNWeb), a system that facilitates the collection of data and maintenance of information about ESRD patients on chronic dialysis or receiving a kidney transplant who are treated in Medicare-certified dialysis facilities and kidney transplant centers in the United States. Excess death estimates were obtained by comparing observed and predicted monthly numbers of deaths during February 1-August 31, 2020; predicted deaths were modeled based on data from January 1, 2016, through December 31, 2019. The analysis estimated 8.7-12.9 excess deaths per 1,000 ESRD patients, or a total of 6,953-10,316 excess deaths in a population of 798,611 ESRD patients during February 1-August 31, 2020. These findings suggest that deaths among ESRD patients during the early phase of the pandemic exceeded those that would have been expected based on previous years' data. Geographic and temporal patterns of excess mortality, including those among persons with ESRD, should be considered during planning and implementation of interventions, such as COVID-19 vaccination, infection control guidance, and patient education. These findings underscore the importance of data-driven technical assistance and further analyses of the causes and patterns of excess deaths in ESRD patients.

Entities:  

Mesh:

Year:  2021        PMID: 34081687     DOI: 10.15585/mmwr.mm7022e2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  11 in total

1.  Evolving Demographics of Nephrology Research Workforce in the United States.

Authors:  Susan E Quaggin; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2021-09       Impact factor: 10.614

2.  Treatment Decision Making for Older Kidney Patients during COVID-19.

Authors:  Thalia Porteny; Kristina M Gonzales; Kate E Aufort; Sarah Levine; John B Wong; Tamara Isakova; Dena E Rifkin; Elisa J Gordon; Ana Rossi; Gary Di Perna; Susan Koch-Weser; Daniel E Weiner; Keren Ladin
Journal:  Clin J Am Soc Nephrol       Date:  2022-06-07       Impact factor: 10.614

3.  ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis.

Authors:  Wisit Prasithsirikul; Tanawin Nopsopon; Phanupong Phutrakool; Pawita Suwanwattana; Piyawat Kantagowit; Wannarat Pongpirul; Anan Jongkaewwattana; Krit Pongpirul
Journal:  Vaccines (Basel)       Date:  2022-06-16

4.  Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak.

Authors:  Megan E Meller; Bridget L Pfaff; Andrew J Borgert; Craig S Richmond; Deena M Athas; Paraic A Kenny; Arick P Sabin
Journal:  Am J Infect Control       Date:  2022-07-19       Impact factor: 4.303

5.  Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era.

Authors:  Allan B Massie; William A Werbel; Robin K Avery; Teresa Po-Yu Chiang; Jon J Snyder; Dorry L Segev
Journal:  Am J Transplant       Date:  2022-04-02       Impact factor: 9.369

6.  COVID-19 Risk Factors and Mortality Outcomes Among Medicare Patients Receiving Long-term Dialysis.

Authors:  Stephen Salerno; Joseph M Messana; Garrett W Gremel; Claudia Dahlerus; Richard A Hirth; Peisong Han; Jonathan H Segal; Tao Xu; Dan Shaffer; Amy Jiao; Jeremiah Simon; Lan Tong; Karen Wisniewski; Tammie Nahra; Robin Padilla; Kathryn Sleeman; Tempie Shearon; Sandra Callard; Alexander Yaldo; Lisa Borowicz; Wilfred Agbenyikey; Golden M Horton; Jesse Roach; Yi Li
Journal:  JAMA Netw Open       Date:  2021-11-01

7.  A Mobile Health-Based Survey to Assess COVID-19 Vaccine Intent and Uptake Among Patients on Dialysis.

Authors:  Sri Lekha Tummalapalli; Daniel Cukor; Andrew Bohmart; Daniel M Levine; Thomas S Parker; Frank Liu; Alan Perlman; Vesh Srivatana; Meghan Reading Turchioe; Said A Ibrahim; Jeffrey Silberzweig
Journal:  Kidney Int Rep       Date:  2021-12-13

Review 8.  COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.

Authors:  Khalil El Karoui; An S De Vriese
Journal:  Kidney Int       Date:  2022-02-14       Impact factor: 18.998

9.  Hospitalizations During the COVID-19 Pandemic Among Recently Homeless Individuals: a Retrospective Population-Based Matched Cohort Study.

Authors:  Michael Liu; Lucie Richard; Michael A Campitelli; Rosane Nisenbaum; Irfan A Dhalla; Rishi K Wadhera; Salimah Z Shariff; Stephen W Hwang
Journal:  J Gen Intern Med       Date:  2022-04-08       Impact factor: 6.473

10.  The Impact of COVID-19 on Patient, Family Member, and Stakeholder Research Engagement: Insights from the PREPARE NOW Study.

Authors:  Teri Browne; Shamika Jones; Ashley N Cabacungan; Katina Lang-Lindsey; Lana Schmidt; George Jackson; Dori Schatell; Kelli Collins Damron; Patti L Ephraim; Felicia Hill-Briggs; Shakur Bolden; Amy Swoboda; Suzanne Ruff; Patty Danielson; Diane Littlewood; Dale Singer; Stephanie Stewart; Brandy Vinson; Diana Clynes; Jamie A Green; Tara S Strigo; L Ebony Boulware
Journal:  J Gen Intern Med       Date:  2022-03-29       Impact factor: 6.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.